Background The CYP2E1 and GSTM1 genes encode metabolic enzymes that have key functions in drug modification and elimination. Methodology/Principal Findings We investigated the possible effects of CYP2E1 and GSTM1 polymorphisms in 71 leprosy patients and in 110 individuals from the general population. The GSTM1*0 null allele and INDEL CYP2E1*1D mutant genotypes were analyzed by conventional PCR, while CYP2E1 SNPs (1053C>T, 1293G>C and 7632T>A) were determined by RT-PCR. In leprosy patients, the GSTM1*0 and CYP2E1*5 alleles and the combined alleles GSTM1*0/CYP2E1*6 and GSTM1*0/CYP2E1*5 were significantly related to a baciloscopic index (BI) (BI<3), while the CYP2E1*6 allele was related to a better clinical evolution in the leprosy spectrum. Conclusions/Significance Therefore, GSTM1*0, CYP2E1*5 and CYP2E1*6 may be possible protection factors for leprosy patients.
References
[1]
Alcais A, Mira M, Casanova JI, Schurr E, Abel I (2005) Genetic dissection of immunity in leprosy. Current Opinion in Immunology 17: 44–48.
[2]
Moreira MBR, Pena GO, Pereira GFM, Madalena M (2002). Ministério da Saúde, Secretaria de Políticas de Saúde, Guia para o controle da hanseníase. ISBN 85-334-0346-1.
[3]
Stretch R (1999) Presentation and treatment of Hansen’s disease. Nurs Times 95(29): 46–7.
[4]
Moreira AS, Ribeiro dos Santos RC, Bastos RR, Silva JV, Santos PM (2006) Conjunctival bacilloscopy in leprosy diagnosis and follow-up. Arq Bras Oftalmol 69(6): 865–9.
[5]
Goulart IMB, Arbex GL, Carneiro MH, Rodrigues MS, Gadia R (2002) Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health. Rev Soc Bras Med Trop 35(5): 453–60.
[6]
Ridley DS, Jopling WH (1966) Classification of leprosy according to immunity: a five-group system. Inernational Journal of Leprosy Other Mycobact. Disease 34: 255–273.
[7]
Kaur MR, Lewis HM (2006) Hidradenitis suppurativa treated with dapsone: a case series of five patients. J Dermatol Treat 17: 211–213.
[8]
Morrison NE, Morley GM (1976) The mode of action of clofazimine: DNA binding studies. Int. J. Lepr 44: 133–135.
[9]
Yano T, Bratinova SK, Teh JS, Winkler J, Sullivan K, Isaacs A, et al. (2011) Reduction of Clofazimine by Mycobacterial Type 2 NADH:Quinone Oxidoreductase. Jour. Bio. Chem. 286: 10276–10287.
[10]
Jopling WH (1983) Side effects of antileprosy drugs in common use. Leprosy Review 54: 261–270.
[11]
Jopling WH (1985) References to “side-effects of antileprosy drugs in common use”. Leprosy Review 56: 61–70.
[12]
Pfaltzgraff RE, Bryceson A (1985) Clinical Leprosy. In: Hastings RC. Leprosy. New York p.134–136.
[13]
Opromolla DVA (1997) Terapêutica da hanseníase. Medicina Ribeir？o Preto 30: 345–350.
[14]
Souza CS (1997) Hanseníase: formas clínicas e diagnóstico diferencial. Medicina Ribeir？o Preto 30: 325–334.
[15]
Rivers EC. Mancera RL (2008) New Anti-Tuberculosis Drugs with Novel Mechanisms of Action. Curr Med Chem 15(19): 1956–67.
[16]
Rivera RC, López CR, Herranz AB, Cevallos MA (2010) Analysis of the Mechanism of Action of the Antisense RNA That Controls the Replication of the repABC Plasmid p42d. Journal of Bacteriology 192: 3268–3278.
[17]
-Hasler JA, Estabrook R, Murray M, Pikuleva I, Waterman M, Capdevila J, et al. (1999) Human cytochromes P450. Molecular Aspects of Medicine 20: 1–137.
[18]
Yamada S, Tang M, Richardson K, Halaschek-Wiener J, Chan M, et al. (2009) Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 10(9): 1433–45.
[19]
Kayaalt？ Z, S？ylemezoglu T (2010) Distribution of ADH1B, ALDH2, CYP2E1*6, and CYP2E1*7B genotypes in Turkish population. Alcohol 1: 9–12.
[20]
Uematsu F, Ikawa S, Kikuchi H, Sagami I, Kanamaru R, et al. (1994) Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics 4(2): 58–63.
[21]
Widersten M, Pearson WR, Engstrom A, Mannervik B (1991) Heterologous expression of the allelic variant Mu-class glutathione transferases m and y. Biochemical Journal 276: 519–524.
[22]
Moyer AM, Salavaggione OE, Hebbring SJ (2007) Glutathione S-Transferase T1 and M1: Gene Sequence Variation and Functional Genomics. Clin Cancer Res 13: 7207–7216.
[23]
Li L, Yang L, Zhang Y, Xu Z, Qin T, et al. (2011) Detoxification and DNA repair genes polymorphisms and susceptibility of primary myelodysplastic syndromes in Chinese population. Leuk Res 35(6): 762–5.
[24]
Cho HR, Uhm YK, Kim HJ, Ban JY, Chung JH, et al. (2011) Glutathione S-transferase M1 (GSTM1) polymorphism is associated with atopic dermatitis susceptibility in a Korean population. Int J Immunogenet 38(2): 145–50.
[25]
Konwar R, Manchanda PK, Chaudhary P, Nayak VL, Singh V, et al. (2010) Glutathione S-transferase (GST) gene variants and risk of benign prostatic hyperplasia: a report in a North Indian population. Asian Pac J Cancer Prev 11(4): 1067–72.
[26]
Hardman JG, Limbird LE (2004) Goodman & Gilman as bases farmacológicas da terapêutica. Raven Press: Rio de Janeiro. 80 p.
[27]
Etienne D, Pieter F, Cairns S (2000) Report of theInternational Leprosy Association Technical Forum: Prevention of disabilities and rehabilitation. Lepr Rev73: S35–S43.
[28]
Vaishali BN, Usha BN, Swati M, Rao P (2011) Evaluation of significance of skin smears in leprosy for diagnosis follow-up, assessment of treatment outcome and relapse. Asiatic Jour. of Biotech. Resources 2(5): 547–552.
[29]
Sambrook J, Fritsch F, Maniatis T (1989) Molecular Cloning: A Laboratory Manual. Cold Spr Harb Laboratory, NY. 2nd edition.
[30]
Santos NPC, Ribeiro-Rodrigues EM, Ribeiro-dos-Santos AKC (2010) Assessing individual interethnic admixture and population substructure using a 48 insertion-deletion ancestry informative markers panel. Hum Mutat. 31(2): 184–90.
[31]
Long J (1999) Multiple Locus Haplotype Analysis, version 2.0. Software and documentation distributed by the author. Section on Population Genetics and Linkage, Laboratory of Neurogenetics, NIAAA, National Institutes of Health, Bethesda.
Douglas JG, Macleod MJ (1999) Pharmacokinetic factors in the modern drug treatment of tuberculosis. Clin Pharmacokinet 37: 127–46.
[34]
Tsutsumi M, Takada A, Wang JS (1994) Genetic polymorphisms of cytochrome P4502E1 related to the development of alcoholic liver disease. Gastroenterology 107: 1430–1435.
[35]
Yang BM, O’Reilly DA, Demaine AG, Kingsnorth AN (2001) Study of polymorphisms in the CYP2E1 gene in patients with alcoholic pancreatitis. Alcohol 23: 91–97.
[36]
Wang SM, Zhu AP, Li D, Wang Z, Zhang P, et al. (2009) Frequencies of genotypes and alleles of the functional SNPs in CYP2C19 and CYP2E1 in mainland Chinese Kazakh, Uygur and Han populations. J. Hum. Genet 54: 372–375.
